Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages.
Journal article
Navarro-Guerrero E. et al, (2021), Sci Rep, 11
-
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Journal article
Lumley SF. et al, (2021), New England Journal of Medicine, 384, 533 - 540
-
Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response.
Journal article
Zhang P. et al, (2021), Cancer Res
-
Targeting IGF perturbs global replication through ribonucleotide reductase dysfunction
Journal article
Rieunier G. et al, (2021), Cancer Research, canres.2860.2020 - canres.2860.2020
-
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Journal article
Wells CI. et al, (2021), International Journal of Molecular Sciences, 22, 566 - 566